The Differences Between Glaucoma and Macular Degeneration
Glaucoma and macular degeneration are two prevalent eye conditions that can lead to severe visual impairment if not addressed promptly.
Menu
Menu
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
Glaucoma and macular degeneration are two prevalent eye conditions that can lead to severe visual impairment if not addressed promptly.
Glaucoma can affect people of all ages, including infants, children, and young people.
“At the GRF Patient Summit, I hope to share the message that there is virtually nothing we can’t do if we learn to navigate the world differently.”
Understanding the connections between glaucoma and other health conditions is crucial because it can help doctors identify patients at higher risk of developing glaucoma.
Access to high-quality information can help patients feel more in control.
The Melza M. and Frank Theodore Barr Foundation Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration began their investigations in 2022.
The Steven and Michele Kirsch Catalyst for a Cure Vision Restoration Initiative (CFC3) is seeking innovative ways to regrow or replace retinal ganglion cells and axons, which make up the optic nerve.
If you have glaucoma, you may be experiencing emotional challenges in addition to the impact of glaucoma on your vision.
“I’ve shifted perspective on my eye health. I took something that used to be a negative and turned it in to a positive.”
The short answer is that “it’s complicated!” This Q&A addresses some common questions.
Currently, there is extensive research and development on “drop-free” or “drop-less” technologies for delivering glaucoma medications to the eye.
GRF’s $50,000 grants initiate creative research ideas.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2023 all rights reserved.
Print Subscription
We will mail Gleams anywhere in the United States and Canada, but we do not mail internationally. Please sign up for the email edition if you live outside of the US or Canada.
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
E-mail Subscription
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.